Suppr超能文献

非经典单核细胞通过 α4β7 整合素归巢至肠道,介导巨噬细胞依赖性肠道伤口愈合。

Non-classical monocyte homing to the gut via α4β7 integrin mediates macrophage-dependent intestinal wound healing.

机构信息

Department of Medicine 1, Kussmaul Campus for Medical Research & Translational Research Center, University of Erlangen-Nuremberg, Erlangen, Germany.

Institute of Experimental Immunology and Imaging, University Duisburg-Essen and University Hospital Essen, Essen, Germany.

出版信息

Gut. 2020 Feb;69(2):252-263. doi: 10.1136/gutjnl-2018-316772. Epub 2019 May 15.

Abstract

OBJECTIVE

To study the role of α4β7 integrin for gut homing of monocytes and to explore the biological consequences of therapeutic α4β7 inhibition with regard to intestinal wound healing.

DESIGN

We studied the expression of homing markers on monocyte subsets in the peripheral blood and on macrophage subsets in the gut of patients with IBD and controls with flow cytometry and immunohistochemistry. Integrin function was addressed with dynamic adhesion assays and in vivo gut homing assays. In vivo wound healing was studied in mice deficient for or depleted of α4β7 integrin.

RESULTS

Classical and non-classical monocytes were clearly dichotomous regarding homing marker expression including relevant expression of α4β7 integrin on human and mouse non-classical monocytes but not on classical monocytes. Monocyte-expressed α4β7 integrin was functionally important for dynamic adhesion to mucosal vascular addressin cell adhesion molecule 1 and in vivo gut homing. Impaired α4β7-dependent gut homing was associated with reduced (effect size about 20%) and delayed wound healing and suppressed perilesional presence of wound healing macrophages. Non-classical monocytes in the peripheral blood were increased in patients with IBD under clinical treatment with vedolizumab.

CONCLUSION

In addition to reported effects on lymphocytes, anti-α4β7 therapy in IBD also targets non-classical monocytes. Impaired gut homing of such monocytes might lead to a reduction of wound healing macrophages and could potentially explain increased rates of postoperative complications in vedolizumab-treated patients, which have been observed in some studies.

摘要

目的

研究 α4β7 整合素在单核细胞肠道归巢中的作用,并探讨针对肠道伤口愈合的 α4β7 抑制的生物学后果。

设计

我们通过流式细胞术和免疫组织化学研究了 IBD 患者和对照者外周血单核细胞亚群和肠道巨噬细胞亚群中归巢标志物的表达。通过动态黏附实验和体内肠道归巢实验研究整合素功能。在缺乏或耗尽 α4β7 整合素的小鼠中研究体内伤口愈合。

结果

经典和非经典单核细胞在归巢标志物表达上明显分为两类,包括人类和小鼠非经典单核细胞上相关的 α4β7 整合素表达,但经典单核细胞上没有。单核细胞表达的 α4β7 整合素对于动态黏附到黏膜血管地址素细胞黏附分子 1 和体内肠道归巢具有重要的功能。α4β7 依赖性肠道归巢受损与(效应大小约 20%)减少和延迟伤口愈合以及抑制伤口愈合巨噬细胞在病变周围的存在有关。在接受 vedolizumab 临床治疗的 IBD 患者中,外周血中的非经典单核细胞增加。

结论

除了对淋巴细胞的报道作用外,IBD 中的抗-α4β7 治疗还靶向非经典单核细胞。这种单核细胞肠道归巢受损可能导致伤口愈合巨噬细胞减少,并可能解释在一些研究中观察到的 vedolizumab 治疗患者术后并发症发生率增加的原因。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验